These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 30811618)
1. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis. Wells LE; Evans T; Hilton R; Wine Lee L; Ruth N Pediatr Dermatol; 2019 May; 36(3):384-385. PubMed ID: 30811618 [TBL] [Abstract][Full Text] [Related]
2. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study. Nash P; Mease PJ; Kirkham B; Singhal A; Quebe-Fehling E; Pricop L; Gaillez C Clin Exp Rheumatol; 2022 May; 40(5):952-959. PubMed ID: 34494957 [TBL] [Abstract][Full Text] [Related]
3. A case of nail psoriasis-associated psoriatic arthritis successfully treated with adalimumab. Ikumi N; Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Kuwana Y; Matsukawa Y; Hayama T; Sawada S; Takei M; Ochiai T Acta Dermatovenerol Croat; 2014; 22(1):65-6. PubMed ID: 24813847 [No Abstract] [Full Text] [Related]
4. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis. Reich K; Baraliakos X; Coates LC; Elewski B; Bao W; Kasparek T; Gaillez C; Pournara E; Aassi M; Perella C; Gottlieb AB Br J Dermatol; 2022 Sep; 187(3):438-441. PubMed ID: 35257363 [TBL] [Abstract][Full Text] [Related]
5. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462 [TBL] [Abstract][Full Text] [Related]
6. Secukinumab efficacy in the treatment of nail psoriasis: a case series. Pistone G; Gurreri R; Tilotta G; Castelli E; Bongiorno MR J Dermatolog Treat; 2018; 29(sup1):21-24. PubMed ID: 30273068 [TBL] [Abstract][Full Text] [Related]
7. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics. Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057 [TBL] [Abstract][Full Text] [Related]
8. Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment. Ismail FF; May J; Moi J; Sinclair R Dermatol Ther; 2020 Mar; 33(2):e13216. PubMed ID: 31899569 [No Abstract] [Full Text] [Related]
9. Psoriasis vulgaris patient with psoriatic arthritis managed with interleukin-17A inhibitor: Balancing benefits and adverse effects. Utama WS; Lestari W; Hajar S; Sylvawani M; Ismida FD; Akele RY Narra J; 2024 Apr; 4(1):e207. PubMed ID: 38798877 [TBL] [Abstract][Full Text] [Related]
10. Biological therapy and nail psoriasis. Lawry M Dermatol Ther; 2007; 20(1):60-7. PubMed ID: 17403261 [TBL] [Abstract][Full Text] [Related]
11. Therapies for psoriatic nail disease. A systematic review. Cassell S; Kavanaugh AF J Rheumatol; 2006 Jul; 33(7):1452-6. PubMed ID: 16724366 [TBL] [Abstract][Full Text] [Related]
12. Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked. Williamson L; Dalbeth N; Dockerty JL; Gee BC; Weatherall R; Wordsworth BP Rheumatology (Oxford); 2004 Jun; 43(6):790-4. PubMed ID: 15113998 [TBL] [Abstract][Full Text] [Related]
13. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: Bagri NK; King H; Ramanan AV Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357 [TBL] [Abstract][Full Text] [Related]
14. Comparative microscopic analysis of nail clippings from patients with cutaneous psoriasis and psoriatic arthritis. Fonseca GP; Werner B; Seidel G; Staub HL An Bras Dermatol; 2017; 92(1):21-25. PubMed ID: 28225951 [TBL] [Abstract][Full Text] [Related]
15. Interventions for nail psoriasis. de Vries AC; Bogaards NA; Hooft L; Velema M; Pasch M; Lebwohl M; Spuls PI Cochrane Database Syst Rev; 2013 Jan; (1):CD007633. PubMed ID: 23440816 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153 [TBL] [Abstract][Full Text] [Related]
17. Nail psoriasis: a review. Tan ES; Chong WS; Tey HL Am J Clin Dermatol; 2012 Dec; 13(6):375-88. PubMed ID: 22784035 [TBL] [Abstract][Full Text] [Related]
18. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. Crowley JJ; Weinberg JM; Wu JJ; Robertson AD; Van Voorhees AS; JAMA Dermatol; 2015 Jan; 151(1):87-94. PubMed ID: 25471223 [TBL] [Abstract][Full Text] [Related]
19. Nail psoriasis in an adult successfully treated with a series of herbal skin care products family a case report. Tirant M; Hercogovấ J; Fioranelli M; Gianfaldoni S; Chokoeva AA; Tchernev G; Wollina U; Novotny F; Roccia MG; Maximov GK; França K; Lotti T J Biol Regul Homeost Agents; 2016; 30(2 Suppl 3):21-8. PubMed ID: 27498654 [TBL] [Abstract][Full Text] [Related]
20. [Successful reduction of NAPPA score (Nail Assessment in Psoriasis and Psoriasis-Arthritis) under secukinumab in severe nail psoriasis]. Alhumam A Dermatologie (Heidelb); 2024 Feb; 75(2):149-152. PubMed ID: 37823915 [No Abstract] [Full Text] [Related] [Next] [New Search]